Breast cancer test kit MAMECAN™

for ERBB2 geneBRCA1 geneBRCA2 gene

Breast cancer is one of the most common types of cancer affecting women, followed by gynecologic cancers, including ovarian, endometrial/uterine, cervical, vulvar and vaginal cancer. Although surgery, radiation, endocrine treatment and chemotherapy are currently major treatment regimens for these cancers, targeted therapy (e.g. HER2 antibodies and PARP inhibitors) and immunotherapy are emerging options for subsets of eligible patients. Some women with breast cancer may also be at risk for developing other cancers, including ovarian cancer, especially when carrying a germline mutation of the BRCA gene. Therefore, comprehensive genetic testing is beneficial for breast and gynecologic cancer patients seeking precision medicine and to evaluate their genetic predisposition to other cancer types. Targets 68 key genes in breast cancer Comprehensive testing of HER2(ERBB2) variants and ER mutations, dysregulation of PI3K-mTOR signaling pathway, and BRCA1/2 deficiency Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers Reveals potential resistance mechanism(s) to current therapy Assesses genetic predisposition to cancers Optional PD-L1 immunohistochemistry (IHC) test to better guide immunotherapy decisions for advanced triple-negative breast cancer (TNBC) patients WHO IS IT FOR Breast cancer patients seeking precision medicine Breast cancer patients resistant to endocrine therapy, chemotherapy or targeted therapy SAMPLE TYPES Tumor tissue (FFPE block/slides, or frozen tissue) Fine needle biopsy Liquid biopsy (plasma and others)